Merida Biosciences is a biotechnology company developing precision therapeutics designed to selectively degrade disease-causing autoantibodies for patients with serious autoimmune and allergic diseases.
Eli Lilly agreed to acquire Merida for up to $2.875 billion in cash, gaining a platform with potential application across a broad range of antibody-driven conditions, including Graves’ disease, thyroid eye disease, and food allergy. Merida’s lead program, MER511, has demonstrated early Phase 1 data in Graves’ disease.
GroveStreet first became a Third Rock Ventures LP in 2007. Read more here.
Learn more about us or reach out to schedule a meeting.